Novo Nordisk is set to benefit from a $150B market by 2030, with strong earnings potential and a favorable 14x forward P/E.

Novo Nordisk has experienced a notable decline in its stock price, dropping by 12.08% over the past week. This downturn comes amid increased competition in the weight loss and dia ...

Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily ...

Shares of Novo Nordisk, the Danish pharmaceutical company behind weight-loss drugs Ozempic and Wegovy, plummeted this week.

Novo Nordisk's stocks face YTD struggles due to trial results and tariffs, but strong fundamentals and outlook justify a Buy.

In a new First Opinion essay, Borio and Krause, both once top FDA officials, say the commissioner made a “rookie misstep” in ...

The tortoise (Eli Lilly) has caught the hare (Novo Nordisk), according to a report from BMO Capital Markets, which cites the ...

Guggenheim downgraded Novo Nordisk (NVO) to Neutral from Buy.Stay Ahead of the Market: Discover outperforming stocks and invest smarter with ...

U.S.-listed shares of Novo Nordisk plunged 7% in intraday trading Thursday after rival Eli Lilly reported positive oral ...

Fintel reports that on April 17, 2025, BMO Capital downgraded their outlook for Novo Nordisk A (NYSE:NVO) from Outperform to ...

Drugmaker Eli Lilly said Thursday that an experimental pill form of popular GLP-1 medications helped people with type 2 diabetes lose an average of nearly 8% of their body weight after 40 weeks and ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Novo Nordisk (NVO – Research Report) and ...